Lipocine (NASDAQ:LPCN) Lowered to “Hold” at StockNews.com

Lipocine (NASDAQ:LPCN) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Alliance Global Partners started coverage on shares of Lipocine in a research report on Tuesday. They issued a “buy” rating and a $10.00 price objective for the company.

Lipocine Trading Down 4.3 %

Shares of LPCN stock opened at $4.44 on Friday. The firm’s fifty day moving average price is $4.43 and its two-hundred day moving average price is $5.55. Lipocine has a 1 year low of $2.31 and a 1 year high of $11.79. The firm has a market capitalization of $23.75 million, a P/E ratio of -2.60 and a beta of 1.21.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million during the quarter. As a group, equities research analysts forecast that Lipocine will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent filing with the Securities & Exchange Commission. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.